By Paige Michael, RN · The Sunshine Edit
In late 2025 the FDA removed the black-box warning from menopausal hormone therapy. It was a major shift, but the details matter. Here is what actually changed and what did not.
For more than twenty years, many women avoided hormone therapy because of a stark warning label and the fear it created. In late 2025, the FDA</a> moved to remove the black-box warning from menopausal hormone therapy products, and it was one of the most significant developments in women’s health in a generation. It is also widely misunderstood. Removing a warning does not mean hormone therapy is right for everyone, and it does not erase every consideration. As a nurse practitioner who manages hormone care, let me explain what changed, what did not, and how to think about it.
What the FDA changed
The FDA moved to remove the boxed warning that had appeared on menopausal hormone therapy products, reflecting an updated reading of the evidence, particularly for women who begin therapy around the time of menopause. The practical effect is that the scariest, most blanket warning, which discouraged a generation of women and their doctors, no longer frames every conversation. For many women who are good candidates, that is a meaningful and overdue change.
What did not change
This is the part the headlines often skip. Removing the boxed warning does not mean hormone therapy carries no risks or suits everyone. Certain cautions remain, including specific warnings that still apply to particular products, such as estrogen-alone therapy. Hormone therapy is still a medical decision that depends on your health history, your symptoms, and your personal risk factors. It is more accessible to consider now, not automatically appropriate.
The timing hypothesis
Much of the updated thinking centers on timing. The evidence increasingly supports the idea that the benefit-to-risk balance is most favorable for women who start therapy around the time of menopause, generally within about ten years of it or before age sixty, rather than starting many years later. Timing is not the only factor, but it is one of the most important, and it is a big part of why the conversation has shifted.
Who might benefit, and who should be cautious
The only way to know which group you’re in is an individualized evaluation — not a headline, and not a friend’s experience. Broadly:
- Often good candidates to at least discuss therapy: women with bothersome menopausal symptoms who are within that earlier window and don’t have specific contraindications.
- May need a more cautious approach or non-hormonal options: women with certain personal or family health histories.
How to talk to your provider
Come to the conversation prepared:
- ☐Bring your symptoms, and your personal and family health history.
- ☐Bring your goals for treatment.
- ☐Ask how the updated guidance applies to your specific situation.
- ☐Ask what the options are, including non-hormonal ones.
- ☐Ask how you’d be monitored.
A good provider won’t hand you a one-size answer — they’ll help you weigh your own picture, now that the outdated warning is no longer standing in the way of an honest discussion.
Frequently asked questions
Is hormone therapy safe now that the FDA removed the warning?
The FDA removed the blanket black-box warning in late 2025, which is meaningful, but it does not mean hormone therapy is right for everyone. It remains a medical decision based on your history, symptoms, and risk factors.
What did the FDA actually change about HRT?
It moved to remove the boxed warning that had appeared on menopausal hormone therapy products, reflecting updated evidence, especially for women who start therapy around the time of menopause.
What did not change about hormone therapy?
Certain cautions remain, including warnings that still apply to specific products such as estrogen-alone therapy. Hormone therapy is more accessible to consider, not automatically appropriate for everyone.
Is there a best time to start HRT?
Evidence increasingly favors starting around the time of menopause, generally within about ten years of it or before age sixty, though timing is one of several factors your provider will weigh.
The bottom line
The FDA’s decision is a genuine turning point that removes an outdated barrier to an honest conversation about hormone therapy. What it does not do is replace that conversation. If menopausal symptoms are affecting your life, this is the moment to talk with a provider about whether hormone therapy fits your individual picture.
Have questions about hormone therapy after the FDA change? Book a hormone consult at Sunshine Wellness for guidance based on your history, not a headline.
Related on FL Innovation News
- The Sunshine Edit — the full column
- Health — more from the Health desk
- Peptides vs. GLP-1s for Weight Loss
- More from Paige Michael, RN
About the author
Paige Michael, RN, is a registered nurse specializing in wellness and aesthetics at Sunshine Wellness & Aesthetics in St. Petersburg, Florida, where she works with patients on medical weight management, hormone support, IV therapy, and injectables. She writes The Sunshine Edit for FL Innovation News. Learn more at sunshinewellnessaesthetics.com.
Read more from Paige Michael, RN on FL Innovation News, or visit sunshinewellnessaesthetics.com.
Medical disclaimer: This article is general information about health topics and is not medical advice. It is not a substitute for a conversation with your own clinician, who can advise on what is appropriate for your circumstances.
